CNO Financial (CNO - Free Report) reported $1.01 billion in revenue for the quarter ended March 2023, representing a year-over-year increase of 19.4%. EPS of $0.51 for the same period compares to $0.42 a year ago.
The reported revenue represents a surprise of +9.54% over the Zacks Consensus Estimate of $918.38 million. With the consensus EPS estimate being $0.65, the EPS surprise was -21.54%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how CNO performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Insurance policy income: $625.50 million versus $628.41 million estimated by four analysts on average.
- Insurance policy income- Annuity riders: $5.10 million versus $5.79 million estimated by three analysts on average.
- Insurance policy income- Health: $401.40 million versus $407.03 million estimated by three analysts on average.
- Other Insurance Margin- Life: $47.40 million compared to the $46.69 million average estimate based on three analysts.
- Insurance policy income- Long-term care: $65.90 million versus $66.84 million estimated by three analysts on average.
- Interest-sensitive Margin- Annuity interest margin: $57.30 million compared to the $43.38 million average estimate based on three analysts.
- Other Insurance Margin- Health: $116.50 million versus $114.46 million estimated by three analysts on average.
- Net investment income (loss)- General account assets: $292.20 million versus $286.90 million estimated by three analysts on average.
- Insurance policy income- Life: $219 million versus the three-analyst average estimate of $216.87 million.
View all Key Company Metrics for CNO here>>>Shares of CNO have returned +1.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
CNO Financial (CNO - Free Report) reported $1.01 billion in revenue for the quarter ended March 2023, representing a year-over-year increase of 19.4%. EPS of $0.51 for the same period compares to $0.42 a year ago.
The reported revenue represents a surprise of +9.54% over the Zacks Consensus Estimate of $918.38 million. With the consensus EPS estimate being $0.65, the EPS surprise was -21.54%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how CNO performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Insurance policy income: $625.50 million versus $628.41 million estimated by four analysts on average.
- Insurance policy income- Annuity riders: $5.10 million versus $5.79 million estimated by three analysts on average.
- Insurance policy income- Health: $401.40 million versus $407.03 million estimated by three analysts on average.
- Other Insurance Margin- Life: $47.40 million compared to the $46.69 million average estimate based on three analysts.
- Insurance policy income- Long-term care: $65.90 million versus $66.84 million estimated by three analysts on average.
- Interest-sensitive Margin- Annuity interest margin: $57.30 million compared to the $43.38 million average estimate based on three analysts.
- Other Insurance Margin- Health: $116.50 million versus $114.46 million estimated by three analysts on average.
- Net investment income (loss)- General account assets: $292.20 million versus $286.90 million estimated by three analysts on average.
- Insurance policy income- Life: $219 million versus the three-analyst average estimate of $216.87 million.
View all Key Company Metrics for CNO here>>>Shares of CNO have returned +1.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CNO - FREE